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DifferentiationThe ﬁbroblast growth factor, FGF8, has been shown to be essential for vertebrate cardiovascular, craniofacial,
brain and limb development. Here we report that Fgf8 function is required for normal progression through
the late fetal stages of lung development that culminate in alveolar formation. Budding, lobation and
branching morphogenesis are unaffected in early stage Fgf8 hypomorphic and conditional mutant lungs.
Excess proliferation during fetal development disrupts distal airspace formation, mesenchymal and vascular
remodeling, and Type I epithelial cell differentiation resulting in postnatal respiratory failure and death. Our
ﬁndings reveal a previously unknown, critical role for Fgf8 function in fetal lung development and suggest
that this factor may also contribute to postnatal alveologenesis. Given the high number of premature infants
with alveolar dysgenesis and lung dysplasia, and the accumulating evidence that short-term beneﬁts of
available therapies may be outweighed by long-term detrimental effects on postnatal alveologenesis, the
therapeutic implications of identifying a factor or pathway that can be targeted to stimulate normal alveolar
development are profound.and Anatomy, and Human
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We previously reported that 100% of Fgf8 deﬁcient newborn mice
die in the ﬁrst postnatal day with cyanosis and respiratory failure
(Frank et al., 2002). Since only 40% of these mutants have predictably
lethal cardiovascular defects, our observations led us to hypothesize
that pulmonary dysfunction due to abnormal prenatal lung develop-
ment may cause respiratory failure and death in these animals, and
here we report our studies conﬁrming this hypothesis.
Correct progression through embryonic, pseudoglandular, canalic-
ular, and saccular stages of prenatal lung development culminates in
alveolar formation after birth, and these stages of lung development are
conserved in many vertebrates (Alcorn et al., 1981; Davies et al., 1988;
Docimo et al., 1991). During the embryonic stage, lung development is
initiated when the primitive foregut endoderm (epithelium) is inducedto invade the surrounding splanchnic mesoderm (mesenchyme) and
form the trachea and the bronchi at embryonic day (E) 9.5 in themouse.
The proximal airways form by branching morphogenesis during the
embryonic (~E10.5–14.5) and pseudoglandular stages (E14–16.5 in
mouse) (Metzger et al., 2008). The canalicular stage (E16–17.5) is
characterized by creation of the pulmonary acinus (air sac), and the
multiplication and canalization of capillaries. During the saccular stage
(E17–19), peripheral airways form terminal clusters of potential air
spaces, and the capillary network and septal cores are remodeled in
preparation for gas exchange at birth. In humans, the alveolar phase of
lung development normally begins in utero during the ﬁnal weeks of
development and continues postnatally (Boyden, 1974; Davies and
Reid, 1970; Emery andWilcock, 1966; Langston et al., 1984),whereas in
the mouse, alveolarization is predominantly a postnatal event. Alveolar
formation is manifest structurally by the protrusion of partitions from
saccular walls (Burri, 1997; Schittny et al., 1998) and subsequent
elongation of those partitions into secondary septa with accompanying
capillaries. Although septal thinning has been attributed to prenatal
mesenchymal apoptosis in rabbits and rats (Bruce et al., 1999),
attenuation of the septal mesenchymal core in mice appears to be
primarily due to elongation and remodeling of the septa prenatally and
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mouse lung at fetal stages (Bird et al., 2007; Muglia et al., 1999; our
unpublished observations).
The mechanisms that regulate initial budding, branching morpho-
genesis and proximal airway development have been intensely
studied. However, late initiation and prolonged duration of alveolar
formation pose signiﬁcant challenges to identifying the genetic and
molecular mechanisms that regulate the late stage lung development
(Boyden, 1974; Burri, 1997; Davies and Reid, 1970; Dunnill, 1962;
Emery and Wilcock, 1966; Langston et al., 1984). Mouse knockout
models have identiﬁed many molecules that regulate embryonic lung
development (Colvin et al., 2001; Lindahl et al., 1997), but this
approach often profoundly affects the earliest stages, and pulmonary
development ceases and/or death occurs prior to the initiation of the
saccular and alveolar stages.
FGF signaling proteins regulate multiple morphogenetic processes
during vertebrate organogenesis (Szebenyi and Fallon, 1999). FGF
receptors (FgfRs) are transmembrane tyrosine kinases. Ligand binding
induces receptor dimerization, autophosphorylation, intracellular
signaling cascades and ultimately, altered gene expression and cell
behavior. Several Fgfs and all known FgfRs (FgfR1–5) are expressed in
the lung (Bellusci et al., 1997; Colvin et al., 1999; Hu et al., 1998;
Powell et al., 1998; Sannes et al., 1992).
The temporospatial expression of FGF ligands and receptors varies
with developmental stage. Fgf10 and Fgf7 are expressed in lung
mesenchyme while Fgf1, Fgf9, and Fgf18 are expressed in both
mesenchyme and epithelia. Fgf8 transcripts have been detected in
embryonic mouse and adult rat lung (Lin et al., 2002; Schmitt et al.,
1996); however expressionof Fgf8 in fetal and postnatalmouse lung has
not previously been described. Germline ablation of some Fgf ligands
and their receptorshas established a central role of reciprocal epithelial/
mesenchymal FGF signaling during the embryonic and pseudoglandular
stages (Arman et al., 1999; Bellusci et al., 1997; Cardoso, 2001;
Warburton et al., 1999), but no FGFs have yet been discovered to
function during the fetal stages. Targeted deletion of either Fgf10 or its
receptor, FgfR2b, inhibits budding of the lung from the trachea (De
Moerloozeet al., 2000;Minet al., 1998; Sekineet al., 1999)whereas later
embryonic ablation disrupts branching morphogenesis (Abler et al.,
2009). FGF9 stimulates mesenchymal proliferation and propagation of
branching in part via stimulating Fgf10 (Colvin et al., 2001). FGF7
stimulates proliferation and differentiation of distal lung in culture
(Cardoso, 2001), but Fgf7-null mice have normal lungmorphology (Guo
et al., 1996). Fgf18 null mutants have lung hypoplasia and decreased
ﬁbroblast proliferation during the canalicular stage but normal distal
epithelial differentiation (Usui et al., 2004).
Although data are somewhat conﬂicting (Celli et al., 1998; Hokuto
et al., 2003; Weinstein et al., 1998; Yi et al., 2006), the overall body of
literature suggests that the fetal saccular to alveolar transition and
postnatal lung development are FGF-dependent processes, however,
no FGF ligands have previously been tested by conditional loss-of-
function sufﬁciently late in lung development to establish which, if
any, are required for saccular or alveolar development.
Here we report that Fgf8 has unique required functions to support
fetal lung development andmay play a role in postnatal alveologenesis.
Our data indicate that FGF8 is required to regulate proliferation in the
fetal stages; in the absence of adequate Fgf8 function, there is
pronounced excess proliferation in both the epithelial and mesenchy-
mal compartments from E16.5 to 18.5 and subsequent disruption of
epithelial differentiation and abnormal septal and vascular remodeling.
Materials and methods
Mice
The Fgf8 null (Moon and Capecchi, 2000), hypomorphic (Frank et
al., 2002) and conditional (Park et al., 2006) alleles are as previouslydescribed and are maintained in 50% each C57Bl6 and SV129
background. The Isl1Cre allele (Park et al., 2006) is in a 50% C57Bl6
and 25% each BlSw and Sv129 background, and the MesP1Cre allele
(Saga et al., 1999) is 50% C57Bl6 and 25% each ICR and SV129.
Lung wet/dry weight ratios
Lung wet/dry weight ratios were determined by use of the
microwave drying technique (Peterson et al., 1982). Brieﬂy, the lungs
were freshly excised and thewet weight determined. The tissueswere
dried in a microwave oven at 200 W for 1 h and then weighed; they
were returned to the oven at 5 minute intervals and re-weighed to
determine when desiccation was complete and the ﬁnal measure-
ment used as the dry weight.
Preparation of RNA and cDNA for microarray and microarray data
analyses
E18.5 lung lobes were dissected away from large airways and
vessels and stored in RLT buffer (Qiagen) at−80 °C. Three specimens
of each genotype (Fgf8+/+, controls; Fgf8H/−, hypomorphic mutants)
were pooled to generate each sample. Total RNA was extracted from
four samples (RNeasy Micro Kit, Qiagen). This experiment was run in
quadruplicate on Agilent mouse whole-genome expression arrays.
Agilent two-color LRILAK labeling, the Agilent two-color GE hybrid-
ization/wash protocol, and the Agilent 5-micron XDR scanning
protocols were carried out by the University of Utah Microarray
Core Facility. The array image data were quantitated using Agilent
Feature Extraction software (version 9.5.1.1). Subtle intensity-
dependent bias was corrected with LOWESS normalization, with no
background subtraction. The raw and normalized data sets have been
submitted to GEO (accession number: gse22893). Spots with intensity
below background were removed prior to statistical analysis.
Statistical analysis of normalized log-transformed data was per-
formed in GeneSifter (www.genesifter.net). Differentially expressed
transcripts were deﬁned (adjusted for multiple testing using the
Benjamini and Hochbergmethod) as Pb0.05. Data were hierarchically
clustered with Spotﬁre (TIBCO) and heat maps for selected genes
were generated. For qRT-PCR validation, total RNA from each of the
initial four pools (100 ng) was reverse transcribed to cDNA using the
SuperScript III First-Strand Synthesis System (Invitrogen). Quantita-
tive RT-PCR was performed with iQ SYBR Green Supermix on the
iCycler system (Bio-Rad) and normalization was to hprt, gapdh and
βactin. Primer sequences will be provided on request.
Real-time quantitative RT-PCR of Fgf8 and Fgf10 transcripts in wild
type lungs
Total RNA was isolated from 5 to 12 pooled lung homogenates
from E11.5 to P5 mice using TriZol reagent (Invitrogen, 15596-026).
After DNase treatment (Qiagen, 79254), RNA was further puriﬁed
using the RNAeasy MinElute Cleanup kit (Qiagen, 74204). cDNA
templates for PCR ampliﬁcation were synthesized from 2 μg of total
RNA using a SuperScript® III First-Strand Synthesis Kit (Invitrogen,
18080-400) in the presence of Oligo dT. qPCR and quantitation were
performed in the Bio-Rad iCycler IQ™ Multicolor Real-Time PCR
Detection System using 25 μl IQ™ SYBR® Green Supermix (Bio-Rad,
170-8882), 250 nM of each primer and 1 μl of cDNA. Each sample was
run in triplicate. The ampliﬁcation ramp included initial hold of 5 min
at 94 °C, followed by a three step cycle consisting of denaturation at
94 °C (30 s), annealing at 57 °C (30 s) and extension at 72 °C (30 s)
and the ampliﬁcation ﬂuorescence was read at the end of the cycle.
The quantitative expression value for each speciﬁc transcript was
normalized to that of the GAPDH. Ratios of Fgf8 and Fgf10 transcripts
at each time point relative to that at E14.5 are shown from E11.5 to P5.
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E15.5 embryonic lungs were isolated and the tissue minced in ice
cold PBS. A single cell suspension was obtained by 0.5% collagenase
(Sigma, C0130) digestion at 37 °C for 45 min and then incubated
with RBC lysis buffer (Sigma, R7757) at RT for 15 min to remove red
blood cells. The cells were ﬁltered through a 100-μm cell strainer
and resuspended in DMEM with 10% fetal calf serum. Mesenchymal
cells and epithelial cells were isolated based on their differential
adherence to culture ﬂask plastic over time. Adherent cells after the
ﬁrst 45 min in culture were mesenchymal cells; the unattached cells
at this 45 minute point were isolated and cultured for an additional
1 h yielding a second batch of attached cells which is a mixture of
epithelial cells and ﬁbroblasts; these were discarded. The persis-
tently unattached cells are epithelial cells, which were then
centrifuged at low speed (120 g×3 min) for isolation. Isolated
epithelial and mesenchymal cells were ﬁxed in 4% PFA for 20 min
on ice and processed immediately. 105 cells in 250 μl PBS buffer
were added to a cytospin chamber and the specimens were
cytocentrifuged at 750 rpm for 3 min, leaving a button of concen-
trated cells on the slide. For qRT-PCR assay of these isolated
populations, cell total RNA sample was prepared using RNAeasy
micro Kit (Qiagen, 74004) with the protocol provided by the
manufacturer. cDNA synthesis and quantitative PCR procedures
were the same as described above.FGF8 stimulation of lung mesenchymal and epithelial cells and analysis
of BrdU incorporation
E15.5 mesenchymal and epithelial cells were isolated as above and
4×105 (epithelial or mesenchymal) cells were plated per well
containing a sterilized 12 mm round coverslip in a 24 well plate.
Each experimental treatment was repeated in triplicate. Cells were
allowed to attach either in the presence or in the absence of serum,
with the simultaneous addition of 20 ng/ml FGF8 with 100 ng/ml
heparin, or heparin alone. The cells were incubated for 24 or 48 h and
BrdU was added to a ﬁnal concentration of 10 μM, cells incubated an
additional 12 h and then rinsed in 1× PBS and ﬁxed in −20 °C 100%
methanol for 30 min. Coverslips were removed from the wells,
washed in PBS, immersed in 2 N HCL for 20 min at room temperature,
washed in 0.1 M sodium borate (pH 8.5) for 2 min at room
temperature. After washing for 5 min in PBS, they were washed 3
times in a blocking solution containing PBS+0.2% Triton X100+3%
BSA for 10 min each and then incubated with BrdU primary antibody
(Abcam, ab6326) in block for 2 h. Antibody was removed by
3×10 minute washes in block and then Alexa 594 goat anti-mouse
secondary was added for I h at room temperature. After ﬁnal washing
in block ×3, the coverslips were mounted in Vectashield with DAPI. 3
randomly selected 200× ﬁelds were counted on each coverslip (3
coverslips per experimental treatment, 9 random ﬁelds counted in
total per experimental treatment group): the total nuclei in living
cells per ﬁeld were counted, as was the subset with BrdU+nuclei. The
percent positive nuclei are expressed as (BrdU nuclei/total nu-
clei)×100. Quantitation of overall cell adherence, growth and survival
(Figs. 5C, D) was performed based on initial plating of 4×105 cells and
each random 200× ﬁeld counted represents 1/67th of the total
surface area of the 12 mm coverslip.Fig. 1. Fgf8 hypomorphic mutants die at birth with dysplastic, hypercellular lungs. A–D) Wh
lungs (C, D) photographed side-by-side; note that in spite of the overall decrease in body siz
are the same size). E–F′) Low (E, F) and high (E′, F′) magniﬁcation photographs of H&E stain
thickened septal walls (compare red arrows in E′ and F′) and location of many red blood cells
the red blood cells are immediately adjacent to the airspaces. TRU; terminal respiratory unImmunoﬂuorescence
For isolated mesenchymal and epithelial cells, the cells were
permeabilized with 0.1% Triton X100 in PBS for 15 min and then
blocked with 5% bovine serum in PBS containing 0.1% Triton X100. For
sectioned lung, the lung was removed and ﬁxed routinely, embedded
in OCT, and sectioned at 10 μm. Immunohistochemical analysis was
performed using the following antibodies: anti-FoxA2 (1:1000;
Abcam, ab40874), anti-PECAM (1:200; BD Pharmingen, 550274),
anti-Nkx2.1 (1:100, GeneTex, 8G7G3/1), anti-SMA (1:100, Sigma,
A2547), anti-Aquaporin-5 (1:100; CalBiochem, 178615), and anti-SPC
(1:200; Upstate 07-647). Trypsin antigen retrieval was used to
unmask the antigen for PECAM detection. Blocking was performed
using 5% of goat or donkey serum in PBST. Antibodies were incubated
O/N at 4 °C. Secondary antibodies conjugated with Alexa 488, Alexa
594 or Cy3 (1:1000; Molecular Probes) were incubated for 1 h at RT.
Slides were mounted using VECTASHIELD mounting medium with
DAPI (Vector Laboratories, H-1200). Images were obtained using a
Zeiss Axio microscope and Zeiss AxioVision software. The anti-SPC
signal was imaged on an IX81 Olympus microscope and images
captured with a Hamamatsu Orca digital camera with a DSU spinning
confocal unit using Slidebook software.
BrdU immunohistochemical staining of mouse lung sections
Mice received intraperitoneal injection of 50 mg/g body weight 5-
bromo-2′-deoxyuridine (Invitrogen, 00-0103) 2 h prior to sacriﬁce.
The lung was removed and processed routinely, embedded in OCT
Compound, and sectioned at 10 μm. Microwave antigen retrieval was
performed for 20 min in Antigen Unmasking Solution (Vector
Laboratories, H-3300). Endogenous peroxidases were quenched by
incubation at room temperature in 1% H2O2 for 20 min followed by
rinsing in PBST (PBS with 0.1% Tween 20). Blocking was performed
using 5% donkey serum in PBST. Rat anti-BrdU primary antibody
(Abcam, ab6326) in 5% donkey serumwas added to the tissue sections
at a 1:1000 dilution. Sections were incubated overnight at 4 °C and
then rinsed in PBST. Biotinylated speciﬁc staining was detected with
biotinylated donkey anti-rat secondary antibody (Jackson ImmunoR-
esearch, 712-065-153) horseradish peroxidase complexes using
VECTASTAIN Elite ABC kits (Vector Laboratories, PK-6100). Antigen–
antibody complexes were visualized using DAB Substrate (Vector
Laboratories, SK-4105). The labeling index was expressed as the
number of BrdU-positive ratio and counted by Image-Pro Plus v.
6.0software (Media Cybernetics, Inc). Results were expressed as
means±SE of at least 3 mice per group and p values were calculated
using Student's two tailed t-test.
β-Galactosidase staining
MesP1 and Islet1 lineage analysis was performed with a standard
breeding strategy in which the females contained the conditional
Rosa26lacz reporter allele (Soriano, 1999) and the males carried the
MesP1Cre or Islet1Cre alleles. E11.5 embryos were stained for β-
galactosidase activity using a standard protocol. All embryos from a
litter were ﬁxed in 0.2% glutaraldehyde in PBS, 0.02% NP40 (PBN) on
ice for 15 min, washed in PBN, and placed in X-gal staining solution
(5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mMole mount E18.5 control (Fgf8H/+) and hypomorph (Fgf8H/−) littermate mice (A, B) and
e of the mutant, the lungs are as large as those in controls (vertical black lines in C and D
ed parafﬁn sections from P0.5 inﬂation-ﬁxed lung preparations. Note the hypercellular,
(pink stained cells, located in capillaries) embedded in the septa whereas in the control
it.
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overnight at room temperature while rocking. After staining, embryos
werewashed in PBN and post-ﬁxed in 4% paraformaldehyde overnight
at 4 °C. Embryos were then rinsed in PBS and cleared in glycerol for
photographs, embedded in parafﬁn, sectioned transversely, and
counterstained with nuclear Fast Red.
Results
Decreased Fgf8 function disrupts lung development
Fgf8 expression is required in multiple temporospatial expression
domains during vertebrate development, and null embryos die early
in embryogenesis (Meyers et al., 1998; Moon and Capecchi, 2000; Sun
et al., 1999). The phenotypes of Fgf8 hypomorphs (produce less than
50% of the normal amount of Fgf8 mRNA) revealed the essential
functions of this protein in cardiovascular, nervous system, limb and
pharyngeal development and left–right patterning (Abu-Issa et al.,
2002; Frank et al., 2002;Meyers et al., 1998;Moon, 2006). Subsequent
conditional mutagenesis experiments have been instrumental in
further dissecting the requirements for Fgf8 activity at different times
and locations (Ilagan et al., 2006; Lewandoski et al., 2000; Macatee et
al., 2003; Moon, 2006; Moon and Capecchi, 2000; Park et al., 2006;
Trumpp et al., 1999).
We previously reported that 100% of Fgf8 deﬁcient hypomorphs
(Fgf8H/−, animals bearing a hypomorphic allele and a null allele of
Fgf8) die in the ﬁrst postnatal day with cyanosis; however, only 40% of
thesemutants have predictably lethal cardiovascular defects (Frank et
al., 2002). We observed these animals after birth and noted that in
spite of signiﬁcant respiratory effort, they uniformly became cyanotic
and died within hours of birth. Thus, we questioned whether
pulmonary defects contribute to their postnatal death and so collected
lungs from Fgf8H/− hypomorphs, and their wild type, null heterozy-
gote (Fgf8+/−) or hypomorph heterozygote (Fgf8H/+) littermates at
E18.5 and immediately after birth (P0.5). On gross pathology at E18.5,
the lungs of the Fgf8H/−mutants aremuch larger relative to total body
size than controls (Figs. 1A–D, fetuses are photographed side-by-side;
longitudinal black bars superimposed over the lungs are the same
length, and the lungs are photographed side-by-side). This correlates
with a signiﬁcantly increased lung to bodyweight ratio in themutants
(6.9±0.7% in Fgf8 hypomorphs versus 4.9±0.8% in controls, p=0.04,
N=4) that is not attributable to edema, because mutants also have
increased dry to wet lung weight ratio (12.9±1.9% in Fgf8 mutants
versus 9.1±0.3% wild type, p=0.02). Thus the mutant lungs are
hyperplastic. In fact, at P0.5 when all controls have generated large air
spaces, thin septa (Figs. 1E, E′ control red arrows), and a well-
organized capillary network, the mutants have dramatically hyper-
cellular septa that appear not to have progressed beyond the early
saccular stage; the capillary network (as visualized by the bright pink
red blood cells in Fig. 1F′) is largely remote from the airspaces
embedded in thick septal walls (Figs. 1F, F′, mutant red arrows).
Thickness of the septal walls in mutants is 150% that of controls (4.9±
0.7 μm controls versus 7.6±1.5 μm mutants, pb0.05, N=6).
Fgf8 is expressed at low levels in the developing mouse lung
Fgf8 mRNA transcripts have previously been detected in E12.5
mouse and adult rat lung (Lin et al., 2002; Schmitt et al., 1996);
however the expression of Fgf8 at other stages has not been
characterized. We assayed Fgf8 transcripts in whole lung lobes from
wild type mice (all proximal airways and vessels were removed) by
quantitative RT-PCR; Fig. 2A shows the expression level at each stage
relative to the level at E14.5 (data shown are normalized to gapdh).
We detected expression at all stages of prenatal lung development,
with a marked increase at postnatal day 5 (P5). Normalization to
βactin also revealed a marked increase in the relative level of Fgf8expression postnatally (not shown). No Fgf8 transcripts were detected
in RNA prepared from Fgf8 null embryo negative controls. The
absolute cycle threshold (Ct) values for Fgf8 in the lung ranged from
29 to 33, indicating a low number of transcripts and consistent with
our inability to detect the mRNA signal above background by in situ
hybridization with digoxigenin- or 35S-labeled antisense riboprobes
(not shown). In contrast, Fgf10 transcripts were detected with
absolute Ct values ranging from 15 to 19 (Fig. 2B) and levels increased
steadily over the course of prenatal lung development, as has been
reported (Bellusci et al., 1997).
To determine whether Fgf8 is expressed in both the mesenchymal
and epithelial cellular compartments of the developing lung, we
dissociated E15.5 lung tissue and isolated epithelial from mesenchy-
mal cells using a protocol adapted from Schuger et al. (1993), based
on the differential adherence of dissociated cells types over time to
standard tissue culture ﬂasks. This method provides excellent
separation of epithelial and mesenchymal cells as demonstrated by
analysis of cytospin preparations of the two populations with
mesenchymal (PECAM, SMA; Figs. 3A, A′, B, B′) and epithelial
(Nkx2.1, FoxA2; C, C′, D, D′) protein markers. When we assayed
these isolated populations for transcript levels using qRT-PCR, and
compared the ratio of transcripts detected in the mesenchymal versus
epithelial compartments, we found that Fgf8 transcripts are relatively
enriched epithelial cells (6.5 fold), along with transcripts for Foxa2
and Shh, while Pecam and Fgf10 transcripts were enriched in
mesenchymal cells, as expected (Fig. 3E). The source of Fgf8
transcripts in lung is not red blood cells or another circulating cell
type, as these experiments were performed after red blood cell lysis,
and we have speciﬁcally found that Fgf8 transcripts are undetectable
in E15.5–17.5 fetal blood (data not shown).
All four Fgf receptors are expressed in the lung (Powell et al., 1998)
and we quantitated the relative levels of FGF receptor transcripts in
these isolated cell populations (Supplemental Table 1). We obtained
the expected ratios for FgfR2b and FgfR2c (enriched in epithelia and
mesenchyme, respectively (Arman et al., 1999)) and detected
expression of FgfR1b and c, FgfR3, and FgfR4. While these data are
not absolute transcript numbers, we have optimized efﬁciency of all
primer sets and thus the dCt values (Ct of the gene of interest less that
of the housekeeping gene) can be compared for relative abundance of
the different FgfR amplicons. These data indicate that FgfR1 isoform b
and c transcripts are present at comparable levels to that of FgfR2 b
and c in the epithelium and mesenchyme, respectively. We were
unable to generate reliable isoform speciﬁc primers for FgfR3; our data
conﬁrm that FgfR3 and FgfR4 transcripts are expressed in both the
epithelial and mesenchymal compartments.Fgf8 deﬁciency causes excess proliferation and disrupts the fetal phase of
lung development
Given the markedly thickened septal walls observed in the
hypomorphs, we tested whether excess proliferation was a contrib-
uting mechanism. We labeled S-phase cells with an intraperitoneal
pulse of BrdU administered to the mother 2 h prior to fetal harvest
and performed anti-BrdU immunohistochemistry atmultiple stages of
lung development. While the percentage of labeled cells was not
different between hypomorphs and controls at the late embryonic and
early fetal stages (E13.5–15.5; Figs. 4A–C), by E16.5, proliferation in
the mutants both visually and statistically exceeded that in controls
by more than 2 fold in both the distal epithelium and mesenchyme
(Figs. 4A, B, C). Furthermore, although the total percentage of
proliferating epithelial and mesenchymal cells decreases in the
hypomorphs at E17.5 and E18.5 (as it does in controls), it remains
abnormally high (Figs. 4A, D). We assayed for apoptosis using the
TUNEL assay in these specimens and found only rare TUNEL+ cells in
both mutants and controls (data not shown).
Fig. 2. Fgf8 is expressed at low levels throughout prenatal lung development and
increases markedly postnatally. Quantitative reverse transcription-PCR was used to
assay Fgf8 (A) and Fgf10 (B) transcript levels in lung tissue prepared from E11.5–P5
specimens. Fold expression is shown relative to that at E14.5 and normalized to gapdh.
Fgf10 quantitation is shown for comparison and increases gradually over this time
period. Ct; cycle threshold value.
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do so in the lung in vivo (Bellusci et al., 1997; Colvin et al., 2001; Usui
et al., 2004). Although the cell proliferation and survival responses to
FGF8 are dosage and context dependent (Storm et al., 2003, 2006), the
hyperproliferative lung phenotype in FGF8 deﬁcient mutants is
nonetheless surprising. To better understand whether excess prolif-
eration of both mesenchymal and epithelial cels in the mutants
represents a direct or secondary consequence of FGF8 deﬁciency, we
assayed whether FGF8 stimulates or represses proliferation of lung
epithelial andmesenchymal cells at E15.5. Isolated cells were cultured
for 24 and 48 h in the presence or absence of serum and recombinant
FGF8b and then pulsed with BrdU and immunostained.
As shown in Fig. 5A, by 24 h FGF8 had signiﬁcantly increased the
percentage of BrdU-positive mesenchymal cells both in the absence
(columns a and b, 2.3 fold increase, pb0.001) and presence (columns c
and d, 1.2 fold increase, pb0.001) of serum, and at 48 h in the absence
of serum (columns e and f, 2.7 fold, pb0.001). The cumulative effects
of adherence to substrate, survival and growth of the cultured
mesenchymal cells on total cell number at the time of counting are
shown in Fig. 5C. At 24 and 48 h in the absence of serum,
approximately 120% of the number of mesenchymal cells initially
plated were present (compare columns a and e) and this was not
signiﬁcantly affected by FGF8 (columns b and f); the negligible
increase in mesenchymal cell number at 48 h in the serum-free
groups is likely attributable to their already being nearly conﬂuent at
24 h. Signiﬁcantly fewer mesenchymal cells were present at 24 h in
the serum-treated groups (columns a versus c, 1.4 fold decrease,
pb0.0001; columns b versus d, 1.2 fold decrease, p=0.02); the reason
for this effect is unclear, but may be due to decreased attachment to
the culture substrate. The lower cell number/lower conﬂuence at 24 h
in the serum-treated cells appears to have permitted cell proliferation
over the next 24 h, as evident by the signiﬁcantly increased number of
cells present at 48 h(columns c versus g, 1.5 fold increase, pb0.0001;
columns d versus h, 1.5 fold increase pb0.0001).
The results obtained with cultured lung epithelial cells were
dramatically different. First, the number of cells surviving as a percent
of the number plated was much lower than for mesenchymal cells in
all groups (Fig. 5D). Unlikemesenchymal cells, the epithelial cellswere
dependent on serum for adherence, growth and survival because at24 h in the absence of serum, there were fewer epithelial cells per well
than in serum-treated wells (Fig. 5D, columns a versus c, 5.2 fold
increase with serum, pb0.0001; columns b versus d, 3.8 fold increase,
pb0.001; columns f versus h, 2.7 fold increase pb0.001). The serum-
free cells did not increase BrdU incorporation in response to FGF8
(Fig. 5B, columns a and b). Most remarkably, in the presence of serum,
FGF8 treatment decreased the percentage of proliferating epithelial
cells at 24 (Fig. 5B, columns c versus d, 1.4 fold decrease, pb0.001) and
48 h(Fig. 5B, columns g versus h, 1.5 fold decrease, pb0.001). After
48 h, the majority of epithelial cells cultured in the absence of serum
had pyknotic nuclei, but we scored those with normal nuclear
morphology and none had incorporated BrdU either in the presence
or absence of FGF8 (Fig. 5B, columns e and f). Although the presence of
serum permitted better survival of epithelial cells to 48 h (Fig. 5D,
columns f versus h), FGF8 nonetheless decreased BrdU incorporation
in these cells (Fig. 5B, columns g and h). In total, these data indicate
that FGF8 at the dosage employed here has opposite effects on BrdU
incorporation in epithelial versus mesenchymal cell types.
In order to obtain a picture of the molecular pathways that were
dysregulated in association with the excess proliferation seen in the
fetal mutant lung, we performed a genome-wide expression analysis
comparing E18.5 Fgf8 hypomorphic lungs to wild type controls. The
direction andmagnitude of the changeswere very consistent between
the 4 arrays, conferring high statistical power to our analysis.
Furthermore, we analyzed expression of 46 genes of interest by
qRT-PCR and in 43, the ﬁndings validated those of the microarray, a
speciﬁcity of 93% (Supplemental Table 2). Microarrays are less
sensitive than qRT-PCR and in this experiment the fold change
reported by the microarray usually underestimated the magnitude of
the changes in transcript levels (or did not detect differences)
detected by qRT-PCR. In addition to examining absolute fold-changes,
we used pathway-based analysis in order to detect modest, yet
potentially functionally relevant changes in the context of multiple
“hits” to a pathway (Curtis et al., 2005; Park et al., 2008). KEGG
analysis revealed that the most overrepresented category of dysre-
gulated genes was “Cell cycle” (60 upregulated, z-score 10.66, heat
map not shown due to large number of genes); the changes were
overwhelmingly in the direction of excess proliferation, consistent
with our BrdU results. Overrepresented downregulated genes in the
“Focal adhesion” pathway (53, z=7.03) and “ECM–receptor interac-
tion” pathway (31, z=7.43) suggest that disrupted contact inhibition
may contribute to the hyperproliferative state. Wnt ligands, receptors
and canonical target gene transcripts were increased, while those of
numerous Wnt inhibitors were decreased (Fig. 6). Of the FGF ligands
expressed in lung, Fgf8 (the level of transcripts inmutant lung assayed
by qRT-PCR was 7.8 fold lower than in controls), Fgf10 (2.3 fold
increased) and Fgf9 (5.7 fold increased) were dysregulated. Expres-
sion of FgfR3 and FgfR4was decreased, while that of FgfRs 1 and 2were
unchanged (Supplementary Table 2). Other ﬁndings relevant to lung
morphogenesis and the Fgf8 mutant fetal/postnatal phenotypes are
shown in the heat maps in Fig. 6. Results are expressed as a fold
change in mRNA level (up—red, down—green) in mutants versus wild
type. Critical mediators of VEGF signaling and vascular maturation
were decreased. The proﬁle of many glucocorticoid target genes is
similar to that reported in glucocorticoid receptor null mutants, which
also have a hyperproliferation phenotype (Bird et al., 2007). ECM
structural, remodeling, and signal modulating genes that are
aberrantly expressed include several encoding metalloproteases, ctgf
(connective tissue growth factor), igfbp3 (IGF binding protein 3), ibsp
(Integrin binding sialoprotein) and loxl2 (lysl oxidase 2). In total, the
gene expression changes and other phenotypic features support the
hypothesis that decreased FGF8 signaling causes dysfunction of
pathways that regulate proliferation, cell–cell and cell–ECM interac-
tions, and differentiation in the distal fetal lung.
Thepresenceof Fgf8 transcripts atmultipledevelopmental stages led
us to hypothesize that the pulmonary phenotype in Fgf8 hypomorphs
Fig. 3. Separation of epithelial and mesenchymal cells from E15.5 lungs reveals enrichment of Fgf8 transcripts in the epithelial compartment. Immunocytochemistry using the
antibodies/markers listed at top to assay isolated mesenchymal (A–D) and epithelial (A′–D′) lung cells. Note that SMA and PECAM are detected as expected in mesenchymal cells
(A and B, respectively) but not in epithelial cells (A′, B′) while Nkx2.1 and FoxA2 label epithelial cells. These staining patterns validate the stringency and speciﬁcity of the cell
isolation method. E) Quantitative reverse transcription-PCR was used to compare transcript levels in the isolated mesenchymal and epithelial cells; Fgf8 transcripts were 6.5 fold
greater in the epithelial cells. Other marker transcripts used as controls were present in the expected cellular compartments.
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however, widespread defects in organogenesis and function, including
variable cardiovascular defects in these hypomorphs could theoretically
have secondary effects on lung development. Furthermore, the
hypomorphic allele contains a neomycin phosphotransferase gene
that can adversely affect function of both adjacent and distant genes
(Frank et al., 2002; Olson et al., 1996) raising the possibility that the lung
phenotype results from dysfunction of a different locus (note that this
would predict that the phenotype would be present in hypomorph
heterozygotes, which is not the case: Figs. 1A, C, E). To test our
hypothesis and rule out possible confounding effects of other loci, we
used a nonhypomorphic conditional allele of Fgf8 (Park et al., 2006) and
two Cre drivers with different temporospatial activities to speciﬁcally
test the effects of Fgf8 loss-of-function on lung development. Isl1Cre is
active in pharyngeal endoderm, including pulmonary epithelial pre-
cursors, and in a subset of mesoderm from E8.5 (Park et al., 2006).
MesP1Cre activity is strictly restricted to anterior mesoderm (Park et al.,2006; Saga et al., 1999), including pulmonarymesenchymal precursors.
The blue β—galactosidase staining in panels E and F of Fig. 7 indicates
regions of Cre-mediated recombination of the ROSA26lacZ Cre reporter
gene (Soriano, 1999). By E10.5, MesP1Cre has already recombined the
reporter throughout the lungmesenchyme (Me, Fig. 7E) and Isl1Cre has
recombined the reporter in the lung epithelia (Ep, Fig. 7F) but only a
subset of the lung mesenchyme. Remarkably, E18.5, Fgf8;Isl1Cre
mutants phenocopy the lung defects of Fgf8 hypomorphs (compare
Figs. 7C, C′ to D, D′): the mutants survive to birth but die with cyanosis
postnatally and their lungs have hypercellular septa and a paucity of
capillaries (Figs. 7D,D′, and Fig. 9). Fgf8;Isl1Cremutants exhibit the same
excess proliferation from E16.5 seen in hypomorphs (Fig. 8). This is in
spite of the fact that proliferation in mesenchyme of controls at E14–5–
16.5 in this genetic background (Bl Swiss/SV129/C57Bl6) is slightly
higher than that seen in the background in which the hypomorphs are
maintained (SV129/C57Bl6) as shown in Figs. 4A, B versus 8A, B. In
notable contrast to the variable cardiovascular phenotypes of Fgf8
Fig. 4. Excess proliferation occurs in the lungs of Fgf8 hypomorphic mutants after E15.5. A) Immunohistochemical detection of BrdU-labeled nuclei (brown staining) in lung sections
at the ages noted at top (E13.5–18.5). Control specimens are shown in the top row and Fgf8 hypomorphic specimens in the bottom row. There is a dramatic increase in the number of
labeled cells in the mesenchyme and epithelia from E16.5 onward (red boxed panels). Note that the morphology of the mutant lung also appears normal prior to E16.5.
B) Quantitation of distal mesenchymal proliferation conﬁrms statistically signiﬁcant increases in number of BrdU-labeled nuclei in mutants at E16.5. **pb0.005. C) Quantitation of
epithelial cell proliferation conﬁrms statistically signiﬁcant increases in number of BrdU-labeled nuclei in mutants at E16.5. **pb0.005. D) Fraction of total (mesenchymal+
epithelial) BrdU-labeled nuclei is signiﬁcantly increased in mutants at both E17.5 and E18.5. **pb0.005.
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cardiac outﬂow tract defect, persistent truncus arteriosus (Park et al.,
2006). Ablation of Fgf8 only in mesodermal lung precursors using
MesP1Cre (Figs. 7B, B′, E) does not recapitulate the mutant phenotype
even though we have shown that Fgf8;MesP1Cre mutants also have
vascular and outﬂow tract defects (Park et al., 2006; Watanabe et al.,
2009). The different lung phenotypes in Fgf8;Isl1Cre versus Fgf8;
MesP1Cre mutants indicate that cardiovascular defects are not the
cause of the lung phenotype in Fgf8;Isl1Cre or Fgf8 hypomorphs. We
have also conﬁrmed the independence of the lung and cardiac outﬂow
tract phenotypes in Fgf8;Hoxa3IresCre mutants (Macatee et al., 2003);
these mutants have pancellular CRE activity caudal to the second
pharyngeal arch from ~E8.5 and although they only rarely have outﬂow
tract defects (Macatee et al., 2003), they also have the lung phenotype
(not shown).
These data cumulatively indicate that the pulmonary and cardio-
vascular phenotypes reﬂect separate requirements for Fgf8 function in
development of the lung versus the heart/great vessels, respectively.
The conditional ablation experiments rule out secondary effects or
dysfunction of other loci as a cause of pulmonary defects in Fgf8
hypomorphic and Fgf8;Isl1Cre conditional mutants, and support ourhypothesis that FGF8 signaling is speciﬁcally required for lung
development. The different tissue speciﬁcities of Isl1Cre and MesP1Cre
suggest that Fgf8 function is required in endodermal precursors of lung
epithelia or later in their derivatives to support late fetal lung
development.
Lung development occurs normally through the embryonic and
pseudoglandular stages in Fgf8;Isl1Cre and hypomorphic mutants, but
is disrupted in the canalicular stage by excess proliferation, failure of
differentiation, and abnormal septal and vascular remodeling
The Fgf8 hypomorphs revealed a great deal about the importance
of proper Fgf8 function for normal lung development, but to avoid
potential confounding pleiotropic effects on lung development in Fgf8
hypomorphs, and to focus our efforts using a deﬁned loss-of-function
mutant with invariant phenotypes, we performed further immuno-
histochemical exploration of the Fgf8 mutant phenotype in Fgf8;
Isl1Cre conditional mutants. All experiments were repeated on a
minimum of 3 mutants (from each class) and littermate control lung
samples at each stage; control and mutant specimens were processed
on the same slide and the results are highly reproducible.
Fig. 5. FGF8 stimulates BrdU incorporation by E15.5 lung mesenchymal cells in culture but represses it in epithelial cells. A, B) Bar graphs representing percentage of BrdU-positive
nuclei under the culture conditions listed. A) FGF8 stimulates BrdU incorporation by cultured E15.5 lung mesenchymal cells in the presence or absence of serum (a, b; c, d; e, f).
**pb0.001. B) FGF8 represses BrdU incorporation by cultured E15.5 lung epithelial cells in the presence of serum (c, d and g, h). **pb0.001, *pb0.01. C, D) Overall adherence, growth
and survival of cultured E15.5 lung cells as reﬂected by the number of total cells present at the time of assay represented as a percent of the number initially plated. C) Fewer
mesenchymal cells are present at 24 h when cultured in the presence of serum regardless of the presence of FGF8 (compare a to c, and b to d) but these cells then proliferate over the
next 24 h to increase the total number of cells by 1.5 fold (g, h). D) Few epithelial cells adhere or survive to 24 h in the absence of serum and FGF8 treatment slightly improves
viability in the ﬁrst 24 h in the absence of serum (a versus, b). Serum dramatically improves the number of cells present at 24 h although these numbers are still b50% of that
achieved by mesenchymal cells and FGF8 has no additive effect to serum (c, d). There are signiﬁcantly fewer cells in the FGF8 treated serum-free group at 48 h (e versus f) and this is
remedied by treatment with serum (h) **pb0.001, *pb0.01.
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late fetal period concurrent with vascular remodeling. Efforts to dissect
the regulation of late fetal and postnatal alveolar development have
been hindered by the fact that lung development in most mouse
models of disrupted lung development is already abnormal at
embryonic stages. However, at the embryonic and early pseudogland-
ular stages (E13.5 and E14.5), Fgf8;Isl1Cre and Fgf8 hypomorphic
mutant lungs have normal FoxA2, Nkx2.1, PECAM and smooth muscle
actin (SMA) immunoreactivity (Supplemental Figs. 1–3). Lung mor-
phology and proliferation were also normal through the pseudogland-
ular and early canalicular stages in Fgf8;Isl1Cre and Fgf8 hypomorphic
mutants (Figs. 4, 8 and Supplemental Figs. 1–3).
To better characterize the abnormalities present at the late fetal
stages we examined numerous immunohistochemical markers in
Fgf8;Isl1Cremutants (Fig. 9) and Fgf8 hypomorphs (Fig. 10) compared
to littermate controls. At E16.5, production of FoxA2 in the distal
airway epithelia and of PECAM in endothelial cells appears compa-rable in Fgf8;Isl1Cre mutants and controls (Figs. 9A, A′). However, at
E17.5, control lungs have progressed to the saccular stage and the
number of FoxA2+ cells present in the distal lung is decreasing
(Fig. 9B, white arrowheads) as immature Type II cells differentiate
into Type I cells. In contrast, the Fgf8;Isl1Cre mutant lung has
persistent cuboidal FoxA2+ cells surrounding rare, small airspaces
(Fig. 9B′, yellow arrowheads). The pattern of PECAM reactivity still
appears normal in Fgf8;Isl1Cre mutants at this stage (Figs. 9E, E′). By
E18.5, the control lung has many large airspaces and an adjacent,
well-organized capillary network encompassing the thin septa in
readiness for gas exchange at birth (Figs. 9C, F). However, Fgf8;Isl1Cre
mutant septa are thickened and hypercellular, and many cuboidal
FoxA2+ cells still line the saccules (Fig. 9C′, yellow arrowheads); the
vessels are intraseptal with decreased PECAM immunoreactivity
(Fig. 9F′, yellow arrowheads). Consistent with the FoxA2 staining
pattern, controls at this stage display very few cuboidal, Nkx2.1+ cells
(Fig. 9G, blue nuclei, green Nkx2.1, white arrowheads) at the airspace
Fig. 6. Pathway-based heatmaps of gene expression changes in E18.5 hypomorphic lung tissue relative to controls. Green symbolizes decreased expression inmutant and red, increased.
The four columns ineachheatmap represent the results fromeachof the four different experiments and showthat the expression changes detectedwerehighly reproducible fromarray to
array. The glucocorticoidmap shows genes that have been previously shown to be dysregulated in glucocorticoid receptor null mutant lungs (Bird et al., 2007). ECM, extracellularmatrix;
CAM, cell adhesion molecule.
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small airspaces in the mutants. The fraction of total cells that are
Nkx2.1+ in wild type lungs at E18.5 was 0.15±0.02, while that in
Fgf8;Isl1Cre mutants was 0.29±0.05, p=0.01. Increased immuno-
reactivity for surfactant protein C in the mutant epithelia (Fig. 9J)
supports the hypothesis that the excess Nkx2.1/FoxA2+ epithelial
population represents Type II alveolar cells that have failed to
differentiate into Type I cells. Fgf8 hypomorphs display the same
immunohistochemical abnormalities at E18.5 (Fig. 10).
Abnormalities in the septa, airway epithelium and capillary
network are even more severe in Fgf8;Isl1Cre mutants just prior to
birth (E19, Figs. 9K–L′). Compared with controls, fewer PECAM+
capillaries are present in Fgf8;Isl1Cremutant lungs and the network is
hypoplastic and aberrantly located within the thickened septa
(yellow, Figs. 9L, L′). The fraction of total cells that are PECAM+ in
wild type lungs at E18.5 was 0.39±0.04, while that in Fgf8;Isl1Cre
mutants was 0.19±0.01, pb0.01. Aquaporin 5+ Type I cells are easily
detected outlining the normal elongated plasma membrane at the air
interface in controls (Fig. 9M, white staining and arrowheads). In Fgf8;
Isl1Cre mutants (Fig. 9N), and Fgf8 hypomorphs (Fig. 10E′), minimal
Aquaporin 5+ signal is present and the rare, faintly staining cells have
failed to develop a normal squamous morphology; this is consistent
with the failed differentiation of Type II cells. Thus, numerous crucial
events that normally occur at the late saccular/early alveolar stages in
preparation for gas exchange at birth fail to occur in Fgf8 mutants.
Discussion
The onset and progression of the Fgf8 mutant lung phenotypes
during fetal lung development indicates that sufﬁcient FGF8 is
produced in Fgf8;Isl1Cre mutants and hypomorphs to achieve a
threshold required for the the embryonic and pseudoglandular stages
of lung development, or that FGF8 is functionally redundant with
other FGFs during these early periods. FGF8 and FGF18 are the most
closely related ligands expressed in the lung epithelium, but the
reported phenotype of Fgf18 null mutants is quite distinct from that of
Fgf8;Isl1Cre and hypomorphic mutants: Fgf18 null mutants have
hypoplastic lungs with decreased cell proliferation and preserved
epithelial differentiation (Usui et al., 2004), while Fgf8mutants have a
hyperplastic phenotype with distal epithelial and mesenchymal
overproliferation, and disrupted distal epithelial differentiation.
Thus FGF8 and FGF18 are not functionally redundant at fetal stages,
and the phenotypes of both classes of Fgf8 mutant indicate that noother FGF can compensate for the loss of FGF8 during fetal lung
development. Furthermore, expression of FGF10 and FGF9 is
increased in FGF8 hypomorphs at E18.5. These ligands stimulate
epithelial and mesenchymal proliferation, respectively, in vivo; if
increased gene expression also results in increased protein levels,
these ligandsmay be contributing to the excess proliferation observed
in mutants.
The accepted paradigm is that FGFs signal in a paracrine fashion to
effect epithelial–mesenchymal communication in the developing
embryo. Speciﬁc ligand/receptor and receptor isoform binding
preferences demonstrated by in vitro binding and mitogenic assays
support this idea (Zhang et al., 2006), and the results of these studies
are frequently extrapolated to infer what the functionally relevant
interactions are in vivo. However, overlapping receptor binding
capacities and expression patterns as well as gene ablation studies in
mice clearly indicate that functional redundancy and “unfavorable”
ligand/receptor interactions not only occur, but have required
functions in vivo (Park et al., 2008; Powers et al., 2000). For example,
no FGF8 isoforms bound or activated the “epithelial” splice forms of
FGFR1–3 in vitro (MacArthur et al., 1995) yet studies by us and others
clearly indicate that FGF8 does signal to some epithelia via FGFR1 in
autocrine loops (Deng et al., 1994; Park et al., 2008; N. Trokovic et al.,
2003; R. Trokovic et al., 2003; and Moon, unpublished). Published in
vitro data indicate that FGFR3c mediates the greatest response to
FGF8, but FGF8 also activated FGFR1 and 2 “c” isoforms and FGFR4 in
these mitogenic assays (Zhang et al., 2006). Work from our lab and
many others in vivo suggest that FGFR1 and 2 are crucial mediators of
FGF8 signaling in different regions of the developing embryo; this
ligand seems to interact with different receptors in a highly context
dependent manner and the ultimate cellular effects are context and
dosage sensitive (Frank et al., 2002; Meyers et al., 1998; Storm et al.,
2003, 2006). The ability of a given FGF ligand to bind a particular cell
in vivo, and the subsequent effects on the cell are determined by
selective ligand/receptor binding and extracellular matrix (ECM)
composition, particularly heparan-sulfate proteoglycans because
these molecules are functional co-receptors for FGFs. Thus it is not
possible to predict a priori what receptor(s) or isoforms are
functional receptors for FGF8 in the lung. Temporospatially regulated
ablation of candidate receptors will be required to address this
question.
Because expression of a soluble dominant-negative form of FgfR2,
isoform 2b (the epithelially-expressed isoform) did not disrupt
postnatal lung development, it has been argued that alveolar
Fig. 7. Loss of Fgf8 function in the epithelia of Fgf8;Isl1Cre conditional mutants phenocopies the lung phenotypes of Fgf8 hypomorphs but ablation in the lungmesenchyme of Fgf8;MesP1Cremutants does not. A–D′) H&E stained parafﬁn sections
from E18.5 lung specimens obtained from mutants with the genotypes listed at top. Low and high magniﬁcation views are shown and were obtained at similar peripheral locations in the lung. B, B′) Ablation of Fgf8 only in the mesenchyme
with MesP1Cre permits normal lung development through fetal development. C, C′) Fgf8 hypomorphic mutant lung phenotype. D, D′) Fgf8;Isl1Cre conditional mutant lung has thickened septa and few airspaces, phenocopying the
hypomorphic lung. E) The ROSA26lacz Cre reporter shows that MesP1Cre is active and recombines in all lung mesenchymal (Me) precursors by E11.5 but no evidence of recombination is detectable in the lung epithelia (Ep). F) The ROSA26lacz
Cre reporter shows that Isl1Cre is active and recombines broadly in lung epithelial precursors by E11.5, but only in a subset of lung mesenchyme.
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Fig. 8. Excess proliferation occurs in the lungs of Fgf8;Isl1Cre conditional mutants after E15.5. A) Immunohistochemical detection of BrdU-labeled nuclei (brown DAB staining) in lung
sections at the ages noted at top (E14.5–18.5). Control specimens are shown in the top row and Fgf8;Isl1Cre conditional mutant specimens in the bottom row. There is an excess in the
number of labeled cells in the mesenchyme and epithelia from E16.5 onward (red boxed sections). Note that morphology of the mutant lung also appears normal prior to E16.5.
B) Quantitation of distal epithelial proliferation conﬁrms statistically signiﬁcant increases in number of BrdU-labeled nuclei in mutants at E16.5. Note that proliferation of both cell
types is increased in the controls in this background as compared to that of the controls in Fig. 4. *pb0.05. C) Quantitation of mesenchymal cell proliferation conﬁrms statistically
signiﬁcant increases in number of BrdU-labeled nuclei in mutants at E16.5. **pb0.005. D) Fraction of total (mesenchymal+epithelial) BrdU-labeled nuclei is signiﬁcantly increased
in mutants at both E17.5 and E18.5. **pb0.005.
103S. Yu et al. / Developmental Biology 347 (2010) 92–108development is FGF-independent (Hokuto et al., 2003). However, this
engineered receptor does not block interactions of all ligands thatmay
interact with FGFR2b, nor with FGFR2c or other FGF receptors (Celli et
al., 1998). Importantly, deletion of both FgfR3/FgfR4 permits normal
prenatal lung development but disrupts postnatal alveolar formation
(Weinstein et al., 1998). More recently, additional evidence indicates
that FGFR3 and 4 play important roles in regulating ECM production,
secondary septation, and other aspects of both normal and pathogenic
alveolar development, such as seen in infants with bronchopulmonary
dysplasia (Boucherat et al., 2007; Park et al., 2007; Srisuma et al.,
2010). It is unknown if FGFR1 or 2 have roles in fetal lung
development, but antagonism of FGFR1 function in postnatal rats
disrupts alveologenesis (Yi et al., 2006). We are performing postnatal
ablation of Fgf8 to determine if this ligand contributes to postnatal
alveologenesis or and if postnatal ablation phenocopies abnormalities
seen in FgfR3/4 deﬁcient mice. The potential roles of FGFR1 and 2 in
alveologenesis also merit further investigation.
The level of Fgf8 transcripts detected in lung epithelial cells
suggests that either the entire epithelium expresses at very low levels,or that only a subset of epithelial cells express Fgf8. Furthermore, the
increased level of mesenchymal proliferation in hypomorphs relative
to Fgf8;Isl1Cre mutants (in which only a subset of mesenchymal cells
have Cre activity, see Figs. 4 and 8) suggests that theremay be additive
Fgf8 functions in lung epithelia and mesenchyme or that the higher
baseline proliferation in the genetic background of the Isl1Cremutants
obscures some aspects of the phenotype. Since ablation of Fgf8
restricted to the mesodermal precursors of the lung using MesP1Cre
does not recapitulate the pulmonary phenotype seen in hypomorphs
or Fgf8;IslCremutants, it is likely that Fgf8 function is required in either
the endodermal precursors of the lung epithelia or, at later stages in
the lung epithelia derived from this endoderm. If Fgf8 function is
required in the epithelial precursors, our data suggest that the affected
cells are not “symptomatic” during the embryonic or pseudoglandular
stages. We are currently investigating the location and fate of Fgf8-
expressing cells in the developing lung using an Fgf8-lineage tracer
gene-targeted line. We hypothesize that excess proliferation due to
loss of autocrine FGF8 signaling causes failure of epithelial differen-
tiation and secondary abnormal mesenchymal and endothelial cell
Fig. 9. Differentiation and vascular remodeling are disrupted at the saccular and early alveolar stages in Fgf8;Isl1Cre conditionalmutants. All panels show immunohistochemical stains
of cryosectioned lung specimens at the ages stated. A–C′) Staining for FoxA2 protein in the distal epithelia (red) from E16.5 to E18.5. There are few FoxA2+ cells lining the forming
airspaces in E17.5 and E18.5 controls (B, C white arrowheads) and a normal pattern in mutants at E16.5 (A′). At E17.5 (B′) and 18.5 (C′) mutants have a paucity of airspaces and
persistent high numbers of FoxA2+ cells (yellow arrowheads) in the developing airspaces. D–F′) Staining of the developing pulmonary vasculature for PECAM immunoreactivity
(green) reveals grossly normal vascular development in the mutants until E18.5; at E18.5 there is less detectable staining (F′, yellow arrowheads). G–H)Consistent with the FoxA2
data, double staining for Nkx2.1 (green) and nuclei (blue) shows a few Nkx2.1+ cells located in the septa, but not lining the airspaces of controls (white arrowheads) while there is
abnormal persistence of many Nkx2.1+ cells lining the small airspaces of the mutants (red arrowheads). I, J) Double staining for surfactant protein C (SPC, red) and nuclei (blue)
shows increased number of SPC+ Type II alveolar cells or a more primitive precursor cell lining the airspaces. K–N) Analysis at E19. Double staining for PECAM (yellow/green) and
nuclei (red) reveals that, relative to controls (K, K′), there is a paucity of distal vessels and vessels are aberrantly located with the thickened septa of the mutants (L, L′) rather than
adjacent to the airspaces. Aquaporin 5 staining reveals paucity of Type I cells lining the airspaces and their aberrant cuboidal morphology in mutants (N, arrowheads) as compared to
their larger surface area and squamous morphology which gives a ﬁne reticular pattern in controls (M, arrowheads).
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epithelial/mesenchymal differentiation and vascular remodeling.
That FGF8 protein has important functions in tissues in which its
transcript levels are low and difﬁcult to detect by standard methods is
not unprecedented; for example, loss of Fgf8 function in the E8.5
pharyngeal mesoderm containing the second heart ﬁeld, where its
expression is very difﬁcult to detect by RNA in situ hybridization,
disrupts outﬂow tract and pharyngeal vascular development (Park et
al., 2006; Ilagan et al., 2006; Watanabe et al., 2009). Unfortunately,
available antibodies are also insufﬁciently sensitive for detection ofFGF8 protein in low-level producing tissues and thus were not useful
for our attempts to localize FGF8 producing cells in the lung (Moon,
unpublished; Sun et al., 2002).
Our ﬁnding of markedly increased proliferation as the ﬁrst
detectable histologic abnormality in Fgf8 mutants suggests that
some targets of the transcriptional effectors of FGF8 in the lung reside
high in the regulatory hierarchy controlling proliferation. The results
in Fig. 5 suggest that FGF8 produced by the epithelium may have
different autocrine (anti-proliferative) and paracrine (pro-prolifera-
tive) effects in vivo. Our data suggest that excess mesenchymal
Fig. 10. Differentiation and vascular remodeling are disrupted at the saccular and early
alveolar stages in Fgf8 hypomorphic mutants. Double staining for surfacant protein C
(SPC, red) and nuclei (blue) shows increased number of SPC+ cells lining the airspaces.
105S. Yu et al. / Developmental Biology 347 (2010) 92–108proliferation seen in the mutants may not be a primary result of FGF8
deﬁciency and that FGF8 does not directly repress proliferation in
these cells but rather, regulates downstream pathways such that the
excess proliferation is a secondary event. An important caveat to this
hypothesis is that in vivo, cellular responses such as proliferation,
differentiation or cell death in different developmental contexts are
very sensitive to the dosage of FGF8 sensitive (Frank et al., 2002;
Meyers et al., 1998; Storm et al., 2003, 2006). An outstanding question
is whether the different effects we observed on BrdU incorporation,
adherence, growth and survival in cultured cells are the result of
differential receptor activation in mesenchymal versus epithelial cells
(Supplemental Table 1), or attributable to relative dosage effects: very
few epithelial cells attach and survive over the initial culture period
and thus the remaining cells may be exposed to a higher ongoing
effective dose of FGF8 than in the mesenchymal cultures. Clarifying
the in vivo effects of FGF8 on proliferation of these different cells types
will require precise temporospatial gene ablation and inducible
transgenic rescue experiments.The E18.5 transcriptional proﬁle (Fig. 6) represents an advanced
stage of the Fgf8mutant phenotype and thus does not reveal the most
proximal molecular defects downstream of loss of FGF8. The
alterations in Wnt pathway gene expression are particularly provoc-
ative because the proﬁle suggests canonical pathway activation
(including upregulation of Wnt7b (Rajagopal et al., 2008)) which
would stimulate proliferation (as would the increases in Shh, Bmp and
FGF activity suggested by the microarray and qPCR expression data,
Fig. 6 and Supplemental Table 2). However, the proﬁle with regard to
Wnt signaling is complicated by increased levels ofWnt5a transcripts;
this ligand has been shown to decrease proliferation in lung and
overexpression stimulated Fgf10 in transgenic mice (Li et al., 2002,
2005; Tai et al., 2009). It will be necessary to determine which
pathways are primarily disrupted at the onset of the phenotype to
identify those that “trigger” the phenotype and whether the
mesenchyme or epithelium is the primary FGF8 target. Expression
analyses of isolated mesenchymal and epithelial cell populations
isolated from earlier stage wild type and mutant lungs are needed to
identify these most proximal molecular events.
The fact thatmany regulators of ECM composition are dysregulated
may provide important insight into the origin and/or progression of
the phenotype. ECM constitution modulates bioavailability and signal
transduction of numerous growth factors and morphogens. Several
regulatory targets of the Ets transcription factors Pea3 andErm that are
regulated by, and mediate transcriptional effects of FGF8 are ECM
remodeling enzymes (Brent and Tabin, 2004; Firnberg and Neubuser,
2002; Moon et al., 2006; Park et al., 2006; Raible and Brand, 2001;
Roehl and Nusslein-Volhard, 2001; Crawford et al., 2001; Crawford
andMatrisian, 1996). Both of these Ets factors are widely expressed in
the lung, and expression of a dominant negative Erm/Engrailed fusion
protein in airway epithelia resulted in excess Type II and absence of
Type I cells (Liu et al., 2003), remarkably similar to what we observe in
Fgf8 mutants. Interrogation of earlier molecular abnormalities in Fgf8
mutants may reveal that the proximal event that stimulates excess
proliferation and ultimately disrupts numerous signaling cascades is
altered ECM composition and intercellular interactions. For example,
CTGF modulates signaling of diverse pathways via effects on the ECM.
IBSP is regulated by Tgfβ and interacts with both matrix metallopro-
teinases and integrins to inﬂuence cell adhesion, epithelial–mesen-
chymal interactions and ECM deposition. Loxl2 is a lysyl oxidase that
catalyzes crosslinking of elastin and collagens, and inﬂuences cell
adhesion and mobility (Peinado et al., 2008).
The IGF pathway regulates proliferation in fetal and postnatal lung
and is normally downregulated as the distal epithelia matures
(Batchelor et al., 1995; Schuller et al., 1995; Boucherat et al., 2007).
IGF ligands, binding proteins (IGFBP) and their receptors are widely
expressed in fetal lung, but it is IGFBPs that are most dynamically
regulated with stage. IGFBP3 inhibits proliferation and causes
apoptosis in some cell lines independently of IGF receptor function
and decreases cell proliferation in the lung (Jones and Clemmons,
1995) and its expression is markedly decreased in the hyperproli-
ferative lungs of Fgf8 mutants.
Another potentially important link between abnormal expression of
Igfbp3 and Loxl2, increased cell density, and the progressively dysplastic
capillary network in Fgf8mutant lungs is raised by a recent report that
these genes are regulated by elements containing Ets binding motifs
adjacent to hypoxia-response elements (Aprelikova et al., 2006;
Salnikow et al., 2008). This suggests that progression of some aspects
of the Fgf8 mutant phenotype may be driven by metabolic demand of
the hyperplastic mutant lung exceeding its blood supply.
Mice born after deﬁcient fetal glucocorticoid signaling die from
respiratory failure; their distal airspaces are abnormally remodeled
and have not progressed past the canalicular stage. They have reduced
numbers of Type I, but not Type II cells, and reductions in surfactant
protein production (Cole et al., 1995, 2004;Muglia et al., 1995). Recent
studies have shown that a major defect in glucocorticoid receptor null
106 S. Yu et al. / Developmental Biology 347 (2010) 92–108mutants is an excess of proliferating cells in both themesenchymal and
epithelial compartments of the distal lung at E18.5 (Bird et al., 2007).
Although CNS malformations in Fgf8 mutants could affect function of
the hypothalamic/pituitary/adrenal axis and fetal glucocorticoid
production, it has been established that lung maturation does not
depend on fetally synthesized glucocorticoids, but rather on those
produced by the mother (Muglia et al., 1995, 1999).
Relatively little is known about the factors that direct pulmonary
vascular development and coordinate it with that of the airways (Perl
et al., 2002; Roman et al., 1998; Warburton et al., 2000). Our
observation of progressive loss of PECAM staining and an attenuated
vascular network in Fgf8mutants will provide an important model in
which to study these molecular and cellular events. Bidirectional
epithelial mesenchymal signaling between respiratory epithelium
and endothelial cells is required for differentiation and maturation of
both populations (Bhatt et al., 2000). Loss of even a single copy of
Vegfa results in early embryonic lethality due to widespread defects in
vasculogenesis and angiogenesis (Carmeliet et al., 1996). Endothelial
cell proliferation reﬂects the relative expression levels of the Vegf
receptors Kdr and Flt-1 throughout the stages of lung development
and vascular reorganization; these receptors mediate opposing
responses that are critical for both vascular and airway morphogen-
esis (Galambos et al., 2002). Kdr expression depends on VEGF
signaling and loss of VEGF and the resultant decrease in Kdr
expression disrupts endothelial and primary saccular septal develop-
ment (Yamamoto et al., 2007), as well as postnatal alveolar formation.
Endothelial PECAM function is also required for airway development
independent of its effects on endothelial cell proliferation and survival
(DeLisser et al., 2006). Thus the decrease in Vegfa transcripts seen on
the microarray (and conﬁrmed by qRT-PCR) combined with
decreased expression of Flt1, Kdr and Pecam is likely highly signiﬁcant
for both the vascular and epithelial aspects of the Fgf8 mutant
phenotype.
Fgf8 mutants have fewer Type I cells and aberrant persistence of
Nkx2.1/SPC positive pneumocytes lining the distal airways. Nkx2.1
(also called Thyroid transcription factor-1) encodes an Nkx family
member that activates expression of several lung-speciﬁc genes and is
required for normal airway branching and epithelial development
(Kimura et al., 1996). Persistent Nkx2.1 expression in the distal lung
epithelia causes Type II cell hyperplasia and inhibits alveolarization
(Wert et al., 2002), similar to what we observe in Fgf8 mutants. This
supports our hypothesis that FGF8 signaling is essential for the
function of speciﬁc pathways that regulate differentiation and
progression from the saccular to the alveolar stage.
Conclusion
Our studies reveal that Fgf8 function is required to correctly
regulate proliferation and support remodeling and differentiation
during the saccular to alveolar transition. The relatively high level of
Fgf8 expression in postnatal lung (Fig. 2, P1 and P5) suggests that this
factor may also play a role in alveologenesis. Our future experiments
will employ temporspatial-speciﬁc conditional loss-of-function to
deﬁne the window of Fgf8 activity required for the saccular to alveolar
transition and test whether this factor is also required for postnatal
lung morphogenesis.
Therapies for alveolar dysplasia, associated surfactant deﬁciency
and progressive lung dysfunction in premature newborns are largely
supportive; even in term infants, alveolar dysgenesis and lung
dysplasias represent serious immediate threats to life and cause
long-term morbidity. Evidence is accumulating that the short-term
beneﬁts of available therapies may be outweighed by long-term
detrimental effects on postnatal alveologenesis. Thus, the therapeutic
implications of identifying a growth factor or molecular pathway that
can be targeted to stimulate normal saccular and alveolar develop-
ment are profound.Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ydbio.2010.08.013.Acknowledgments
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